Public Health England (PHE) PPE Guidelines

Public Health England (PHE) PPE Guidelines

6th April 2020

Dear Colleagues,

Public Health England (PHE) have now produced updated guidance on recommended PPE, endorsed by the four Chief Medical Officers, which is attached. We would like to offer some guidance that interprets these principles in the context of cardiology-specific scenarios.

This guidance adopts an approach in which the PPE strategy is dependent upon both (a) the location in which patient contact occurs and (b) the likelihood that the contact will involve an aerosol generating procedure (AGP).

For cardiology, this applies to any procedure requiring or likely to require resuscitation for cardiac arrest involving CPR ± intubation and to transoesophageal echocardiography. These procedures require disposable gloves, fluid resistant gowns, a filtering face piece respirator and eye/face protection wherever they are performed (termed type 2 PPE). Other procedures require disposable gloves, plastic apron (when not scrubbed), fluid resistant surgical mask and eye protection (termed type 1 PPE).

Ward environments are covered within the PHE guidance.

For catheter lab procedures the PHE guidance can be applied to the individual case by the assessment of the senior clinician, together with senior cath lab staff, taking into account (a) the likelihood that the patient has the virus and (b) the chance the procedure will be AGP. Our recommendations for the catheter lab are:

For primary PCI and other situations where the patient is admitted directly to the lab or via a resuscitation area in a haemodynamically unstable state the default is that the first operator, assistant and others with direct patient contact (within 1 metre) should wear type 2 PPE.
Note 1. It may well be the case that in many catheter labs, every member of staff will be within 1 metre of the patient at some point during the case. Note 2. If some members of staff are not wearing type 2 PPE and there is a cardiac arrest, those staff should leave the lab immediately and only return if wearing full PPE.

For patients admitted to the lab already intubated or where there is felt to be a very high risk of arrest with prolonged resuscitation then all those within the lab to wear type 2 PPE.

For other situations the cath lab, when deemed low risk of AGP, can be regarded as an inpatient area or operating theatre with suspected or confirmed COVID cases and type 1 PPE is recommended for all those with direct patient contact (within 1 metre).

We recognise that there is a divergence of views within cardiology; we offer here a consensus to advise our members how they can approach PPE for the procedures they undertake and hope that this will provide some clarity.

Recommended PPE for healthcare workers by secondary care inpatient clinical setting, NHS and independent sector 

COVID-19 Safe ways of working: A visual guide to safe PPE 

Nick Curzen
President
British Cardiovascular Intervention Society

Simon Ray
President
British Cardiovascular Society

Alistair Slade
President Elect
BHRS

Important information from the Competitions and Markets Authority: Your requirements as ‘private’ consultants

Important information from the Competitions and Markets Authority: Your requirements as ‘private’ consultants

30th September 2019

As you know, consultants who offer private treatment services are under a legal obligation to be transparent about the typical fees they charge patients for private consultations and procedures.

The Private Healthcare Information Network (PHIN) has been set up as a one-stop shop for patients to find all the information they need when considering a private procedure, and as it grows it is important for consultants to have a presence there – so they can be found by new patients, as well as to fulfil their legal obligations.

PHIN has been mandated to collect performance and costs information and publish this information to better inform patients on their website, following an investigation by the Competition and Markets Authority (CMA) in 2014, which found a lack of transparency in the costs that patients can expect to pay when accessing private care. The lack of transparency is particularly felt by those who self-fund. This is the group that often has the least information about the cost of their procedure and are most vulnerable to unforeseen charges.

PHIN will also be publishing performance information on consultants, provided by the private and NHS hospitals at which they work. Consultants can review the information PHIN holds on them to check it for accuracy and completeness, to ensure that patients get reliable information on the consultants who treat them. To log onto the PHIN consultant portal please use this link: https://portal.phin.org.uk

These requirements are part of the Private Healthcare Market Investigation (Variation and Commencement) Order 2017.

PHIN has provided a range of support guides for consultants new to the process:

Guide to logging onto the PHIN Portal

https://portal.phin.org.uk/Lists/Resource/PHIN%20Portal%20Log%20in%20steps.pdf

Guide to submitting fees to PHIN

https://portal.phin.org.uk/Lists/Resource/PHIN%20Consultant%20fee%20submission.pdf

We encourage all consultants that see patients on a private basis to engage proactively with this process. This is not only a legal requirement, but is also important for providing patients with all the necessary information when considering their care. It’s also useful for you to have a presence on PHIN, so new prospective patients can find you.

If you have any questions please don’t hesitate to contact the PHIN team at consultants@phin.org.uk

Reopro / Abciximab national stocks running low

Reopro / Abciximab national stocks running low

9th October 2017

See document for full details

 

In summary

• There is a temporary interruption of supply for ReoPro® that is likely to result in shortages to patients for the time period between October 2017 and March 2018.

• We estimate that hospital pharmacies will be out of stock by October 2017 or earlier.

• Please consider alternative medications such as other glycoprotein IIb/IIIa antagonists or Bivalirudin instead of ReoPro.